• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Feb. 4, 2013

View Archived Issues

Bulls Proved Right: Hyperion's Ravicti Wins Approval in UCD

The recent spike in Hyperion Therapeutics Inc.'s stock proved to be warranted Friday, when the FDA issued an approval for Ravicti (glycerol phenylbutyrate) for the chronic management of some urea cycle disorders (UCDs) in patients, ages 2 and older. Read More

SEC Panel: Adjusted Tick Size 'Mite' Aid Newly Public Firms

As small biotech firms and others struggle with ways to go public and stay afloat after they do, the Securities and Exchange Commission's (SEC) Advisory Committee on Small and Emerging Companies met for the third time to sort through possible relief routes. Read More

S1 Biopharma Aims for Female Viagra for HSDD Sans Hormones

When Nick Sitchon set out to identify a first product for his start-up, S1 Biopharma Inc., the medical school dropout turned entrepreneur chatted with his mother and hit (potential) pay dirt with her very first idea: "Why not develop something for me and my low libido?" Read More

Research Alliance Seeks to Accelerate Drug Development

A new collaboration among six of the world's largest translational research centers is designed to strengthen discovery efforts at academic and not-for-profit drug development institutes, ultimately improving the rate at which early stage technologies are advanced into commercial therapeutics. Read More

'Support Cells' Star in Lack of Sleep's Antidepressant Effects

"For much of the 1900s, we studied neurons" to understand brain function, Philip Haydon told BioWorld Today. "And the reasons were purely technical. . . . We could listen to neurons, and we could talk to them." Neurons communicate electrically, and electrical recording and stimulation techniques made them amenable to studying. But in terms of what goes on in the brain, looking only at neurons is bound to deliver a minority report. Read More

Financings Roundup

• Stemline Therapeutics Inc., of New York, closed its initial public offering of 3.8 million shares, including the exercise in full of the overallotment option covering 497,647 shares, at a price of $10 per share. Read More

Other News To Note

• Antabio, of Lebege, France, said it received a €4.7 million (US$6.4 million) Wellcome Trust Seeding Drug Discovery Award to develop small-molecule drugs for the treatment of life-threatening infections caused by multidrug-resistant Gram-negative bacteria. Read More

Stock Movers

Read More

Pharma: Other News To Note

• Shire plc, of Dublin, Ireland, said it reached agreement in principle to resolve the previously disclosed civil investigation into Shire's U.S. sales and marketing practices relating to Adderall XR (mixed amphetamine salts), Vyvanse (lisdexamfetamine dimesylate) and Daytrana (methylphenidate transdermal system). Read More

Clinic Roundup

• Tekmira Pharmaceuticals Corp., of Vancouver, British Columbia, said that complete results from a Phase I trial of its RNAi therapeutic, ALN-VSP have been published. Read More

Bench Press: BioWorld Looks at Translational Medicine

Tuberculosis infects a third of the global population, and getting those rates down has been a major challenge, in part because the tuberculosis bacterium can hide out in a latent state where it does not divide for long periods of time. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 20, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 18, 2025.
  • Brain, syringe hovering over hands

    NICE rejects Lilly‘s Kisunla and Eisai‘s Leqembi

    BioWorld
    To no great surprise, the U.K.’s health technology assessment body has found that the benefits of the first two approved Alzheimer’s disease drugs are too small...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 17, 2025
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe